Valneva SE (NASDAQ:VALN – Get Free Report) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 59,700 shares, a decline of 22.9% from the June 30th total of 77,400 shares. Based on an average daily volume of 11,100 shares, the short-interest ratio is presently 5.4 days. Approximately 0.1% of the company’s shares are sold short.
Valneva Stock Performance
NASDAQ:VALN remained flat at $7.25 during trading hours on Friday. 1,907 shares of the company’s stock traded hands, compared to its average volume of 5,476. The firm has a 50 day moving average price of $7.77 and a 200 day moving average price of $7.90. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The stock has a market cap of $504.89 million, a P/E ratio of -17.68 and a beta of 2.20. Valneva has a 1 year low of $6.58 and a 1 year high of $15.28.
Valneva (NASDAQ:VALN – Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.12. The business had revenue of $35.56 million during the quarter, compared to analysts’ expectations of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. On average, sell-side analysts anticipate that Valneva will post -0.5 EPS for the current fiscal year.
Institutional Investors Weigh In On Valneva
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Valneva in a research note on Monday, July 22nd.
View Our Latest Analysis on Valneva
Valneva Company Profile
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
- Five stocks we like better than Valneva
- Compound Interest and Why It Matters When Investing
- Why Call Options Volume for These 2 Stocks Spiked Together
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 7/22 – 7/26
- Options Trading – Understanding Strike Price
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.